000258098 001__ 258098
000258098 005__ 20231004134643.0
000258098 0247_ $$2doi$$a10.3389/fneur.2023.1170360
000258098 0247_ $$2pmid$$apmid:37213901
000258098 0247_ $$2pmc$$apmc:PMC10196068
000258098 0247_ $$2altmetric$$aaltmetric:147555265
000258098 037__ $$aDZNE-2023-00560
000258098 041__ $$aEnglish
000258098 082__ $$a610
000258098 1001_ $$0P:(DE-2719)9001084$$aKlose, Veronika-Felicitas$$b0$$eFirst author$$udzne
000258098 245__ $$aCSF oligoclonal IgG bands are not associated with ALS progression and prognosis.
000258098 260__ $$aLausanne$$bFrontiers Research Foundation$$c2023
000258098 3367_ $$2DRIVER$$aarticle
000258098 3367_ $$2DataCite$$aOutput Types/Journal article
000258098 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1686044356_28876
000258098 3367_ $$2BibTeX$$aARTICLE
000258098 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000258098 3367_ $$00$$2EndNote$$aJournal Article
000258098 520__ $$aAmyotrophic Lateral Sclerosis (ALS) is characterized by progressive motoneuron degeneration through cell autonomous and non-cell autonomous mechanisms; and the involvement of the innate and adaptive immune system has been hypothesized based on human and murine model data. We have explored if B-cell activation and IgG responses, as detected by IgG Oligoclonal bands (OCB) in serum and cerebrospinal fluid, were associated with ALS or with a subgroup of patients with distinct clinical features.IgG OCB were determined in patients affected by ALS (n=457), Alzheimer Disease (n=516), Mild Cognitive Impairment (n=91), Tension-type Headache (n=152) and idiopathic Facial Palsy (n=94). For ALS patients, clinico-demographic and survival data were prospectively collected in the Register Schabia.The prevalence of IgG OCB is comparable in ALS and the four neurological cohorts. When the OCB pattern was considered (highlighting either intrathecal or systemic B-cells activation), no effect of OCB pattern on clinic-demographic parameters and overall. ALS patients with intrathecal IgG synthesis (type 2 and 3) were more likely to display infectious, inflammatory or systemic autoimmune conditions.These data suggest that OCB are not related to ALS pathophysiology but rather are a finding possibly indicative a coincidental infectious or inflammatory comorbidity that merits further investigation.
000258098 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x0
000258098 536__ $$0G:(DE-HGF)POF4-354$$a354 - Disease Prevention and Healthy Aging (POF4-354)$$cPOF4-354$$fPOF IV$$x1
000258098 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x2
000258098 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000258098 650_7 $$2Other$$aage of onset
000258098 650_7 $$2Other$$aamyotrophic lateral sclerosis
000258098 650_7 $$2Other$$acerebrospinal fluid
000258098 650_7 $$2Other$$aintrathecal synthesis
000258098 650_7 $$2Other$$aoligoclonal bands
000258098 650_7 $$2Other$$asurvival
000258098 7001_ $$0P:(DE-2719)9001441$$aJesse, Sarah$$b1$$udzne
000258098 7001_ $$aLewerenz, Jan$$b2
000258098 7001_ $$0P:(DE-2719)9001967$$aKassubek, Jan$$b3$$udzne
000258098 7001_ $$0P:(DE-2719)9001951$$aDorst, Johannes$$b4$$udzne
000258098 7001_ $$0P:(DE-2719)9002007$$aTumani, Hayrettin$$b5$$udzne
000258098 7001_ $$0P:(DE-2719)2812633$$aLudolph, Albert C$$b6$$udzne
000258098 7001_ $$0P:(DE-2719)2812851$$aRoselli, Francesco$$b7$$eLast author$$udzne
000258098 773__ $$0PERI:(DE-600)2564214-5$$a10.3389/fneur.2023.1170360$$gVol. 14, p. 1170360$$p1170360$$tFrontiers in neurology$$v14$$x1664-2295$$y2023
000258098 8564_ $$uhttps://pub.dzne.de/record/258098/files/DZNE-2023-00560%20SUP.TIF
000258098 8564_ $$uhttps://pub.dzne.de/record/258098/files/DZNE-2023-00560.pdf$$yOpenAccess
000258098 8564_ $$uhttps://pub.dzne.de/record/258098/files/DZNE-2023-00560%20SUP.gif?subformat=icon$$xicon
000258098 8564_ $$uhttps://pub.dzne.de/record/258098/files/DZNE-2023-00560%20SUP.jpg?subformat=icon-1440$$xicon-1440
000258098 8564_ $$uhttps://pub.dzne.de/record/258098/files/DZNE-2023-00560%20SUP.jpg?subformat=icon-180$$xicon-180
000258098 8564_ $$uhttps://pub.dzne.de/record/258098/files/DZNE-2023-00560%20SUP.jpg?subformat=icon-640$$xicon-640
000258098 8564_ $$uhttps://pub.dzne.de/record/258098/files/DZNE-2023-00560.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000258098 909CO $$ooai:pub.dzne.de:258098$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000258098 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001084$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000258098 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001441$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b1$$kDZNE
000258098 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001967$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b3$$kDZNE
000258098 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001951$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b4$$kDZNE
000258098 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9002007$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b5$$kDZNE
000258098 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812633$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b6$$kDZNE
000258098 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812851$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b7$$kDZNE
000258098 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x0
000258098 9131_ $$0G:(DE-HGF)POF4-354$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Prevention and Healthy Aging$$x1
000258098 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x2
000258098 9141_ $$y2023
000258098 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-18
000258098 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000258098 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-05-11T13:11:28Z
000258098 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-05-11T13:11:28Z
000258098 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-18
000258098 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2022-11-18
000258098 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000258098 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2022-11-18
000258098 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bFRONT NEUROL : 2022$$d2023-08-23
000258098 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-23
000258098 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-23
000258098 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-08-23
000258098 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2021-05-11T13:11:28Z
000258098 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-23
000258098 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-23
000258098 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-08-23
000258098 9201_ $$0I:(DE-2719)1910001$$kAG Roselli$$lMetabolic Changes$$x0
000258098 9201_ $$0I:(DE-2719)1910005$$kAG Zhan ; AG Zhan$$lNeuroepidemiology$$x1
000258098 9201_ $$0I:(DE-2719)5000077$$kClinical Study Center ; Clinical Study Center Ulm$$lClinical Study Center Ulm$$x2
000258098 980__ $$ajournal
000258098 980__ $$aVDB
000258098 980__ $$aUNRESTRICTED
000258098 980__ $$aI:(DE-2719)1910001
000258098 980__ $$aI:(DE-2719)1910005
000258098 980__ $$aI:(DE-2719)5000077
000258098 9801_ $$aFullTexts